People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CuraSen Therapeutics, Inc. | — | Biotechnology | Series B | $68.6M | $38.6M | 2024 |
Simon Sereda Tate, Ph.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Simon Sereda Tate, Ph.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kathleen Sereda Glaub | 1 | 3 |
| Liam Sereda Ratcliffe | 1 | 2 |
| Benjamin Sereda Potter | 1 | 1 |
| Loretta Sereda Tse, Ph.D. | 1 | 1 |
| Anthony P. Ford | 1 | 1 |
| Patrick Sereda Enright | 1 | 1 |
| Simon Sereda Tate | 1 | 1 |
| Henry Sereda Skinner | 1 | 1 |
| Ron Sereda Hunt | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.